Developing novel drugs for the treatment of cancer. First lead compound advancing up to clinics, has proven in vitro and in vivo efficacy and a good pharmacology profile.
First indication sought is the treatment of malignant mesothelioma: a rare, aggresive and incurable cancer with limited therapeutic options.
We are looking a round of 6.3 milion euros to complete manufacture and perform first in man clinical studies.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.